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Table 1
Standard pediatric vaccines compatible
with PCV13.4–8
Diphtheria
Tetanus
Acellular or whole cell pertussis
Haemophilus inﬂuenzae type b
Inactivated poliomyelitis
Hepatitis B
Meningococcal serogroup C
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CV13: proven efﬁcacy and safety
This discussion is based on a presentation given at a satellite
ymposium held in Buenos Aires, Argentina, on November 20,
009, at the 6th World Congress of the World Society for Pediatric
nfectious Diseases.
Second-generation pneumococcal conjugate vaccines (PCVs),
ncluding 10-valent PCV and 13-valent PCV (PCV13), have recently
een licensed in multiple countries worldwide. PCV13 is an
ligosaccharide/polysaccharide capsular antigen conjugated with
he nontoxic mutant protein CRM197 of diphtheria toxoid, the
ame carrier protein used in the 7-valent vaccine (PCV7).
In addition to the 7 Streptococcus pneumoniae serotypes covered
n PCV7 (4, 6B, 9V, 14, 18C, 19F, and 23F), PCV13 also includes
erotypes 1, 3, 5, 6A, 7F, and 19A. The inclusion of serotypes
A and 19A in PCV13 will provide additional direct pediatric
overage, and serotypes 1, 3, 5, and 7F will provide additional
titis media coverage. Coverage of all of these serotypes will
ollectively provide generally improved global coverage against
nvasive pneumococcal disease (IPD).
Studies conducted in Italy1 and Spain2 have demonstrated
hat the immunogenicity of PCV13 in a 2+1 schedule is compa-
able to that of PCV7. PCV7 administered in a 2+1 schedule has
ocumented efﬁcacy against IPD.3 Because PCV13 is designed to
e interchangeable with PCV7 at any point in the immunization
chedule, countries that are using PCV7 in the 2+1 schedule should
e able to transition directly to PCV13. Furthermore, PCV13 was
ound to be noninferior to PCV7 when given concomitantly with
ost of the standard pediatric vaccines (Table 1), and it did not
dversely affect the safety and/or immune responses of any of the
oadministered vaccines.4–8Varicella
PCV13=13-valent pneumococcal con-
jugate vaccine.
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Preventing pneumococcal disease in adults
This discussion is based on a presentation given at a satellite
symposium held in Buenos Aires, Argentina, on November 20,
2009, at the 6th World Congress of the World Society for Pediatric
Infectious Diseases.
Pneumococcal infection accounts for about 500,000 cases of
pneumonia each year in the United States and is associated with
considerable morbidity and mortality.1 Pneumonia symptoms
(i.e., fever, myalgia, dyspnea, cough, and fatigue) tend to persist,
with median times to resolution ranging from 3 days for fever to
14 days for cough and fatigue; 35% of patients have ≥1 unresolved
symptom at day 28.2 The 30-day mortality rate among patients
with pneumococcal pneumonia admitted to the intensive care
unit remains high compared with that of patients admitted to the
general ward (23% vs 4%, respectively; P<0.001).3The 23-valent pneumococcal polysaccharide vaccines (PPSVs)
currently available were licensed in 1983, replacing the earlier
14-valent formulation that was licensed in 1977.1 The Centers for
Disease Control and Prevention Advisory Committee on Immu-
